Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Account Payables (2019 - 2026)

Revolution Medicines has reported Change in Account Payables over the past 7 years, most recently at -$10.5 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 135.76% year-over-year to -$10.5 million; the TTM value through Dec 2025 reached $9.5 million, up 247.49%, while the annual FY2025 figure was $9.5 million, 247.49% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$10.5 million at Revolution Medicines, down from $19.5 million in the prior quarter.
  • Over five years, Change in Account Payables peaked at $29.4 million in Q4 2024 and troughed at -$29.0 million in Q1 2024.
  • A 5-year average of $2.3 million and a median of -$151500.0 in 2021 define the central range for Change in Account Payables.
  • Biggest five-year swings in Change in Account Payables: skyrocketed 5317.46% in 2022 and later plummeted 2658.1% in 2024.
  • Year by year, Change in Account Payables stood at $2.6 million in 2021, then crashed by 158.57% to -$1.5 million in 2022, then surged by 1712.81% to $24.3 million in 2023, then rose by 20.81% to $29.4 million in 2024, then plummeted by 135.76% to -$10.5 million in 2025.
  • Business Quant data shows Change in Account Payables for RVMD at -$10.5 million in Q4 2025, $19.5 million in Q3 2025, and $8.8 million in Q2 2025.